Back to Cell Types

Lu-135Homo sapiens (Human)Cancer cell line

Also known as: Lu135, LU135, LU-135, NCC-c-Lu-135

🤖 AI SummaryBased on 11 publications

Quick Overview

Human lung cancer cell line with known mutations in DCC and p53 genes, used in cancer research.

Detailed Summary

Lu-135 is a human lung cancer cell line derived from small cell lung carcinoma (SCLC). It is characterized by specific genetic alterations, including mutations in the DCC gene and the p53 tumor suppressor gene. These mutations are associated with the development and progression of lung cancer. The cell line is utilized in research to study the molecular mechanisms of cancer, particularly focusing on the role of tumor suppressor genes and their mutations in carcinogenesis. Lu-135 is also used to investigate the effects of various treatments and to understand the genetic basis of drug resistance in lung cancer.

Research Applications

Study of DCC gene mutations in lung cancerAnalysis of p53 gene mutationsInvestigation of tumor suppressor gene inactivationCancer drug resistance studies

Key Characteristics

Mutations in DCC geneMutations in p53 geneSmall cell lung carcinoma origin

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1389
Species	Homo sapiens (Human)
Tissue Source	Lung[UBERON:UBERON_0002048]

Donor Information

Age	69
Age Category	Adult
Sex	Male

Disease Information

Disease	Small cell lung cancer
Lineage	Lung
Subtype	Small Cell Lung Cancer
OncoTree Code	SCLC

DepMap Information

Source Type	JCRB
Source ID	ACH-001549_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Gly244Cys (c.730G>T)	Unspecified	-	PubMed=28273451, PubMed=22931248
MutationSimple	RB1	p.Arg661fs*1 (c.1980_1983delCCGG)	Homozygous	-	Unknown, PubMed=8263009

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

10

D13S317

7

D16S539

11

D18S51

17,19

D21S11

29,30

D3S1358

17

D5S818

13

D7S820

11

D8S1179

11,15

FGA

22

Penta D

9,11

Penta E

11

TH01

9

TPOX

11

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.

Kasai F., Fukushima M., Miyagi Y., Nakamura Y.

Hum. Cell 37:944-950(2024).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.

Inazawa J.

Am. J. Pathol. 161:207-216(2002).

Mutation and expression of the DCC gene in human lung cancer.";

Yokota J.

Neoplasia 2:300-305(2000).

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Int. J. Oncol. 15:927-934(1999).

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

J. Cancer Res. Clin. Oncol. 120:143-148(1994).

Changes in cell characteristics due to culture conditions in cell lines from human small cell lung cancer.

Hirohashi S., Yamaguchi K., Kato K., Ichinose H., Nagatsu T.

Jpn. J. Clin. Oncol. 16:203-212(1986).

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Saijo N.

Cancer Chemother. Pharmacol. 27:263-270(1991).

Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.

Sugimura T., Terada M., Yokota J.

Oncogene 7:451-457(1992).